



Original article

The urogenital microbiome in chronic kidney disease patients on peritoneal dialysis



Ricardo Araujo^{a,*}, Ana Merino-Ribas^{a,b,c}, Luciano Pereira^{a,d}, Joana Campos^a, Nádía Silva^d, Inês Soares Alencastre^a, Manuel Pestana^{a,d}, Benedita Sampaio-Maia^{a,e}

^a Nephrology & Infectious Diseases R&D Group, i3S – Instituto de Investigação e Inovação em Saúde, INEB – Instituto de Engenharia Biomédica, Universidade do Porto, Porto, Portugal

^b Nephrology Department, Hospital Universitari de Girona Doctor Josep Trueta, Girona, Spain

^c Universitat Autònoma de Barcelona, Barcelona, Spain

^d Nephrology Department, Centro Hospitalar Universitário de São João, Porto, Portugal

^e Faculdade de Medicina Dentária, Universidade do Porto, Porto, Portugal

ARTICLE INFO

Article history:

Received 10 March 2023

Accepted 27 August 2023

Keywords:

Urogenital microbiome
Urobiome
Human microbiome
Gut microbiome
Urinary tract infection
Peritoneal dialysis
Chronic kidney disease

ABSTRACT

Introduction and objectives: Diabetes, dyslipidemia, older age, gender, urinary tract infections, and recent antibiotic intake have been associated with a decrease in the urobiome richness and other fluctuations in this microbiome. Gut and blood microbiome have been reported to be altered in patients with chronic kidney disease (CKD), and specifically in peritoneal dialysis (PD) patients. Still, there are currently no studies describing the urogenital microbiome in CKD-PD patients. In this study we characterized the urobiome profile in 46 PD patients and analyzed its clinical and inflammatory parameters.

Materials and methods: Mid-stream urine, fecal and blood samples were collected from 46 patients undergoing PD at Centro Hospitalar Universitário de São João (CHUSJ) in Porto, Portugal. Exclusion criteria were age under 18 years old, inability to give informed consent, history of infection in the last three months, and antibiotic intake in the last three months. The microbiome communities were analyzed by amplification and sequencing of the V3–V4 region of the bacterial 16S rRNA gene. Correlations with the patients' clinical data and inflammatory profile were performed.

Results: CKD-PD patients presented a unique urobiome profile dominated by Bacillota, Actinomycetota and Pseudomonadota and characterized by a lower Shannon diversity than fecal and blood microbiome. The taxonomic profiles of urogenital samples were organized in multiple subtypes dominated by populations of *Lactobacillus*, *Staphylococcus*, *Streptococcus*, *Gardnerella*, *Prevotella*, *Escherichia-Shigella*, being similar to other non-PD-CKD patients. Gender, sCD14, residual diuresis and history of peritonitis were significantly associated to variations in the urobiome. Although not reaching statistical significance, diabetes and the

* Corresponding author.

E-mail address: ricjparaujo@yahoo.com (R. Araujo).

<http://dx.doi.org/10.1016/j.nefro.2024.04.004>

2013-2514/© 2023 Sociedad Española de Nefrología. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

time on PD also showed association with particular taxonomic groups. Depletion of *Gardnerella*, *Staphylococcus*, *Corynebacterium*, *Lactobacillus* or *Dermabacter* populations correlated with CKD-PD patients with history of diabetes, history of peritonitis and altered levels of sCD14.

Conclusions: Our results highlight urogenital microbiome as a potential partner and/or marker in the overall health state of CKD-PD patients.

© 2023 Sociedad Española de Nefrología. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

El microbioma urogenital en pacientes con enfermedad renal crónica en diálisis peritoneal

R E S U M E N

Palabras clave:

Microbioma urogenital
Urobioma
Microbioma humano
Microbioma intestinal
Infección del tracto urinario
Diálisis peritoneal
Enfermedad renal crónica

Introducción y objetivos: Diabetes, dislipemia, edad avanzada, género, infecciones del tracto urinario y toma reciente de antibióticos, entre otras, se han asociado a una disminución en la riqueza del urobioma y a otras fluctuaciones de dicho microbioma. Recientemente, se han descrito alteraciones en los microbiomas intestinal y en sangre en pacientes con enfermedad renal crónica (ERC) y, específicamente, en pacientes en diálisis peritoneal (DP). A pesar de ello, aún no existen estudios que describan el microbioma urogenital en pacientes en DP. En el presente trabajo, caracterizamos el urobioma en 46 pacientes en DP.

Pacientes y métodos: Se recogieron muestras de orina (micción espontánea), heces y sangre de 46 pacientes en DP del Centro Hospitalar Universitario de São João en Oporto, Portugal. Los criterios de exclusión fueron edad menor a 18 años, incapacidad para entender el consentimiento informado, e historia de infección y toma de antibióticos en los últimos 3 meses. Las comunidades microbiológicas fueron analizadas por amplificación y secuenciación de las regiones V3-V4 del 16S rRNA bacteriano. Se realizaron correlaciones con los datos clínicos y el perfil inflamatorio de los pacientes.

Resultados: Los pacientes en DP presentaron un urobioma único dominado por Bacillota, Actinomycetota y Pseudomonadota, y caracterizado por una menor diversidad de Shannon que los microbiomas en sangre e intestinal. Los perfiles taxonómicos de las muestras urogenitales se organizaron en múltiples subtipos dominados por poblaciones de *Lactobacillus*, *Staphylococcus*, *Streptococcus*, *Gardnerella*, *Prevotella*, *Escherichia-Shigella*, siendo similar al descrito para otros pacientes con ERC no en DP. Género, factor sCD14, diuresis residual y antecedentes de peritonitis se asociaron de forma significativa a cambios en el urobioma. Diabetes y tiempo en DP también se asociaron con grupos taxonómicos específicos, aunque no de forma estadísticamente significativa. La deplección de *Gardnerella*, *Staphylococcus*, *Corynebacterium*, *Lactobacillus* o *Dermabacter* se correlacionó con antecedentes de diabetes, historia de peritonitis y niveles alterados de sCD14.

Conclusiones: Nuestros resultados subrayan la importancia del microbioma urogenital como potencial biomarcador del estado de salud de nuestros pacientes en DP.

© 2023 Sociedad Española de Nefrología. Publicado por Elsevier España, S.L.U. Este es un artículo Open Access bajo la licencia CC BY-NC-ND (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Introduction

Chronic kidney disease (CKD) is a worldwide health problem carrying a high socioeconomic burden with elevated morbidity and mortality.¹ CKD may progress to different stages resulting in a decrease of the ability of the kidneys to excrete liquids and toxic products in the urine. When the estimated glomerular filtration rate (eGFR) is lower than 15 mL/min per 1.73 m², patients with CKD require renal replacement therapy including kidney transplantation, hemodialysis, and peritoneal dialysis (PD).² In PD the peritoneum acts as a high

vascularized dialysis membrane and allows the removal of water and solutes from the internal milieu. In comparison to hemodialysis, PD might enable a better quality of life for the patients, and can also preserve the residual renal function of the patients for a longer period.³ Therefore, CKD-PD patients may maintain residual diuresis for longer periods and at higher values than hemodialysis patients. Still, PD-related infections, specially peritonitis and catheter exit-site infections, represent the major problem of PD units, as these infections can be responsible for catheter loss, transfer to hemodialysis, prolonged hospitalization, and, in more severe cases, death of these patients.⁴

Gut microbiome has been shown to be altered in CKD-PD patients.⁵⁻⁷ These alterations, also known as gut dysbiosis, contribute to the chronic inflammatory state of these patients. Particularly in the gut, CKD-PD patients present a significantly decreased bacterial diversity and a gut microbiome dominated by urease containing indole- and p-cresyl-forming bacteria.⁸ Inversely, taxa linked to the production of probiotic butyrate, short-chain fatty acids (SCFAs), and carbohydrate fermentation appear to be markedly reduced.⁹ A reduction in SCFAs production may be linked to longer dialysis duration, higher peritoneal glucose exposure, and loss of residual renal function. A recent study also correlated PD-protein-energy wasting with a decrease in butyric acid-producing bacteria, namely *Roseburia* and *Phascolarctobacterium*, and with an increase of bacteria associated to intestinal permeability, inflammation, and nutritional imbalance, such as *Escherichia*.¹⁰ *Dorea*, *Clostridium*, and *SMB53* were reported to be less abundant in CKD-PD patients with peritonitis, suggesting that these bacteria may have anti-inflammatory roles.¹¹ A recent study also proposed a decrease in the ratio Bacillota/Bacteroidota (formerly Firmicutes/Bacteroidetes) as a potential biomarker of *Escherichia coli* peritonitis in these patients.¹² Beyond the gut, blood and peritoneum microbiomes were also recently described to be compromised in CKD-PD patients.^{7,13,14}

Urine has been considered throughout the history a sterile fluid. However there is evidence showing that the urinary tract of healthy individuals without urinary infection is dominated by different kinds of viable microbes and the distribution pattern of these microorganisms may affect the urinary tract health.¹⁵⁻¹⁷ Urinary microbiome, or urobiome, is an emerging topic in health and disease, specifically in urinary tract disorders.^{15,17,18} Such differences could be observed in both bladder and voided urine.¹⁷ Urinary dysbiosis has been associated with urinary tract infections and incontinence,¹⁹ overactive bladder syndrome,^{20,21} neuropathic bladder,^{16,22} chronic prostatitis,²³ nephrolithiasis,²⁴⁻²⁶ and urinary tract neoplasms,²⁷ and other systemic factors such as diabetes, dyslipidemia, older age, gender, and recent antibiotic intake.^{28,29} For example, patients with kidney stone disease and hypertension had a unique microbiome profile and such changes may reflect disease progression and may be useful to monitor response to treatments.²⁴ Also, some studies have observed a different urine microbiome composition in CKD patients when comparing with individuals with normal kidney function¹⁸ and a reduction of diversity associated to a decrease in renal function.³⁰ Besides, some studies on the urinary microbiome of CKD-kidney transplant recipients (KTR) revealed an overall decrease in diversity and emergence of opportunistic pathogens promoting antibiotic resistance.^{31,32} Moreover, alteration in the urinary microbiome of KTR have been related to chronic allograft dysfunction and increased susceptibility to infection.²⁰

There are still no studies describing the urogenital microbiome (by testing voided urine) in CKD-PD patients, possibly due to the loss of residual renal function and, consequently, their diuresis. Therefore, this study aimed to evaluate the urogenital microbiome of CKD-PD patients' population ($n=46$) by throughput sequencing and compare it with their gut and circulating (blood) microbiomes. Also, we aimed to analyze the patients' inflammatory markers.

Materials and methods

Patient selection and sample collection

This cross-sectional observational study included 46 CKD patients undergoing PD at Centro Hospitalar Universitário de São João in Porto, Portugal. We invited all the prevalent patients from the PD unit that had a medical appointment at the hospital's outpatient clinic during the four months of recruitment period (September 2018 to January 2019), except those with exclusion criteria. The exclusion criteria for this study included age under 18 years old, inability to give informed consent, history of infection in the last three months, and antibiotic intake in the last three months. Clinical and demographic information was collected for each participant, regarding gender, age, CKD etiology, diabetes mellitus, dyslipidemia, obesity (defined as body mass index of 30 kg/m² and higher), and cardiovascular disease (peripheral vascular disease, ischemic cardiopathy, or cerebrovascular disease). The modality of PD (automated or manual), pharmacological treatment, and history of infection were also registered.

Blood samples were collected in the PD unit, as previously described.⁷ At the same day, the self-collected stool and mid-stream urine specimens were brought refrigerated by the patient within 4 h or 48 h after self-collection, for urine and stool samples, respectively. When stool was collected more than 4 h before out-patients consultation, they were frozen. After aliquoted, the whole blood, urine, and stool samples were immediately frozen and stored at -80°C until microbiome analysis.

Routine clinical analyses were performed testing proteinuria, and serum levels of urea, albumin, hemoglobin, cholesterol, low-density lipoprotein (LDL), high-density lipoprotein (HDL), triglycerides, phosphorus (P), calcium (Ca), calcium phosphate product, ferritin, B-type natriuretic peptide (BNP), parathyroid hormone (PTH), sedimentation velocity (SV), C-reactive protein (CRP), creatinine clearance (C_{creat}), residual renal function, and K_t/V (urea). K_t/V (urea) is a parameter that measures adequacy to PD using urea weekly clearance normalized by urea estimated distribution volume. Tumor necrosis factor α (TNF- α), IL-1, IL-6, IL-10 were determined in plasma by Luminex Multiplex Assay (Millipore). ELISA kits were used to evaluate lipopolysaccharide-binding protein (LPS-BP, Cloud-clone Corp[®]), Toll-like receptor 4 (TLR4, Cloud-clone Corp[®]), and soluble CD14 (sCD14, Quantikine[®] ELISA).

Sample processing for microbiome analysis

Genomic DNA was isolated in a strictly controlled environment at Vaiomer SAS (Labège, France). Total DNA was extracted from whole blood (100 μL) and urine using a protocol carefully designed to minimize risks of contamination.³³ Extraction of DNA from feces was done using QIAamp Fast DNA Stool Mini Kit (Qiagen). Negative controls (molecular grade water added in an empty tube, the same used for sample storage and PD solution) were used simultaneously with the tested samples. PCR amplification was performed using universal primers targeting the V3-V4 region of the bacterial 16S rRNA gene (340F-781R) to encompass 476-base pair

amplicon. The usage of 2 × 300 paired-end MiSeq kit V3 was followed. Sample multiplexing and sequencing library generation were conducted, as previously described.³³ qPCR was used to quantify the DNA concentration in the pool employing a 7900HT Fast Real-Time PCR System (Life Technologies) and KAPA Library Quantification Kits for Illumina Platform (Kapa Biosystems, Inc.). The final pool with a concentration between 5 and 20 nM (after dilution) was used for sequencing in a MiSeq Illumina device, as previously suggested.¹³

16S rRNA gene sequencing analysis

The targeted gene regions were initially analyzed using the FROGS bioinformatics pipeline established by Vaioomer SAS (Labège, France).³⁴ Some filters were applied as previously suggested¹³: (1) amplicons with a length <350 nt or a length >480 nt were removed; (2) amplicons without the two PCR primers were removed (10% of mismatches were authorized); (3) amplicons with at least one ambiguous nucleotides ('N') were removed; (4) operational taxonomic units (OTUs) identified as chimera (with search v1.9.5) in all samples in which they were presented were removed; (5) OTU with an abundance lower than 0.005% of the whole dataset abundance were removed, and (6) OTU with a strong similarity (coverage and identity ≥80%) with the phiX (library used as a control for Illumina sequencing runs) were removed. OTU were obtained via single-linkage clustering and the taxonomic assignment performed by Blast+ v2.2.30+ with the RDP v11.4 databank.

Statistics and data analysis

Primer v7 (PRIMER-e, Auckland, New Zealand) was used for the calculation of diversity indices, as well as, non-metric multidimensional scaling (NMDS) and principal coordinate analyses (PCO), and other multivariate analyses, mainly analysis of similarities (ANOSIM) and permutational multivariate analysis of variance (PERMANOVA), used to test the significance of β-diversity. The percentage of each OTU per sample was used for these analyses, followed by squared root transformed data, resemblance matrices of similarity data types using Bray–Curtis similarities, adding dummy value and testing 4999 permutations. The reads in each sample were initially converted into percentage values according to the total number of sequences in the sample to eliminate the effect of the final number of reads.³⁵ Post hoc analyses were done in STAMP 2.1.3³⁶ and the statistical tests used for multiple groups were one-way analysis of variance (ANOVA), Tukey–Kramer (0.95) and Eta-squared for effect size, while two groups were analyzed using Welch's t-test (two-sided, Welch's inverted for confidence interval method).

Results

Urobiome characterization in CKD-PD patients

The detailed characterization of patients on peritoneal dialysis included in this study is shown in [Tables 1 and 2](#).

The bacterial microbiomes evaluated in this study resulted in a total of 1127 OTUs obtained from the analysis of urine,

Table 1 – Characterization of chronic kidney disease patients on peritoneal dialysis (CKD-PD).

	CKD-PD
Age, years	56.9 ± 10.7
Sex, % male	65.2%
CKD etiology, %	
Diabetic nephropathy	23.9%
Hepatorenal polycystic	21.7%
IgA nephropathy	8.7%
Urologic	8.7%
Others	13.0%
Unknown	21.7%
PD duration, months	31.3 ± 29.7
PD type, %	
Automated PD	50.0%
Continuous ambulatory PD	50.0%
Creatinine clearance, L/week	115.5 ± 56.7
Residual renal function, mL/min	5.7 ± 4.0
K _r /V (urea)	2.2 ± 0.5
Residual diuresis, cm ³ /24 h	115.5 ± 56.7
History of peritonitis (last 24 months)	11*
History of urinary infection (last 24 months)	4#

* Cases caused by *Staphylococcus epidermidis* (n = 2), *Streptococcus salivarius* (n = 2), *Rhizobium radiobacter*, *Klebsiella oxytoca*, *Streptococcus mitis*, *Pantoea* spp., *Serratia marcescens*, and unidentified agent (n = 2). Patients with infections in the last 3 months were excluded from this study and are not included here.

Cases caused by *Escherichia coli* (n = 2), *Streptococcus haemolyticus*, and unidentified agent. Patients with infections in the last 3 months were excluded from this study and are not included here.

gut, and blood samples from 46 CKD-PD patients. A set of 583 OTUs were found in urine samples, while gut samples showed 542 OTUs, and blood samples 514 OTUs. Regarding the Shannon diversity, urine showed the lower diversity in comparison to the gut and blood diversity: the median values was 2.29 for urine (ranging from 1.19 to 4.14), 3.41 for gut (2.39–4.09), and 2.66 for blood (1.79–3.09), with significance difference among all groups of samples ($p < 0.001$). Regarding to other diversity indexes, urine samples showed a richness of 11.3 (range 2.0–44.7) and an evenness of 0.5 (range 0.1–0.8). The taxonomic profiles among the three habitats were distinct ([Fig. 1A](#)). Urine samples were dominated by Bacillota, similarly to gut samples, but also comprised Actinomycetota (formerly Actinobacteria), and Pseudomonadota (formerly Proteobacteria). At family level, Streptococcaceae, Enterobacteriaceae, Lactobacillaceae, Family XI, and Bifidobacteriaceae were the most frequent groups in urine samples ([Fig. 1B](#)). The microbiome of the tested samples was significantly different comparing urine, gut, and blood ($p = 0.001$, [Fig. 2](#)).

The taxonomic profiles allowed to organize the urogenital samples in multiple subtypes, comprising samples dominated by *Lactobacillus*, *Staphylococcus*, *Streptococcus*, *Gardnerella*, *Prevotella*, *Escherichia-Shigella*, or others ([Fig. 3](#)). The value of these subtypes is complex, but it is not related to active urinary infections (because patients with active infections were excluded). Nevertheless, all urogenital samples of *Lactobacillus* subtype were linked to female patients, while the *Staphylococcus* and *Anaerococcus* dominated samples were exclusively found in male patients.

Table 2 – Demographic and clinical characterization of PD-CKD patients and the association of these variables with urinary microbiome. Results expressed in mean and standard deviation (mean ± SD) for continuous variables and number of patients (n) and prevalence (%) for categorical variables; for statistical analysis, continuous variables were transformed in categorical variables.

Variable	Mean ± SD	Specificity	n (%)	p value
Gender		Female	15 (33%)	0.001
Age, years	56.10 ± 10.66	More than 65 years	9 (20%)	0.600
		Less than 51 years	14 (30%)	0.700
Time in peritoneal dialysis, years	2.68 ± 2.45	More than 5 years	5 (11%)	0.090
		Less than 1 year	12 (26%)	0.170
Type of peritoneal dialysis		Automated	22 (48%)	0.460
History of peritonitis		Presence	11 (24%)	0.018
Iron supplementation		On	35 (76%)	0.600
Hypouricemic agents		On	18 (39%)	0.350
Phosphate binders		On	39 (85%)	0.150
Diabetes		Presence	14 (30%)	0.055*
Obesity		BMI higher than 30	5 (11%)	0.230
Cardiovascular disease		Presence	10 (22%)	0.230
Neoplasm		Present or previous	9 (20%)	0.390
Adragao index		No calcification	12 (26%)	0.660
Charlson index		Less than 2	12 (26%)	0.380
Creatinine clearance, L/week	114.09 ± 56.21	Less than 50 L/week	3 (7%)	0.021
Urea, mg/dL	126.37 ± 37.02	Higher than 150 mg/dL	10 (22%)	0.930
Urea depuration, K _t /V	2.22 ± 0.52	Less than 1.7	6 (13%)	0.470
Renal clearance total, mL/min	5.62 ± 3.94	Less than 10 mL/min	18 (39%)	0.150
Residual diuresis, cm ³ /24 h	1301.04 ± 830.69	Higher than 1500 cm ³ /24 h	19 (41%)	0.029
Proteinuria	1.01 ± 1.25	Presence	39 (85%)	0.020
Albumin, g/L	37.03 ± 3.33	Less than 35 g/L	11 (24%)	0.063
Cholesterol, mg/dL	171.48 ± 55.86	Higher than 200 mg/dL	9 (20%)	0.360
C-reactive protein, mg/L	5.25 ± 8.33	Higher than 10 mg/L	6 (13%)	0.560
Ferritin, ng/mL	361.75 ± 218.09	Higher than 600 ng/mL	6 (13%)	0.220
Hemoglobin, g/dL	11.5 ± 61.42	Higher than 12 g/dL	15 (33%)	0.690
Erythrocyte sedimentation rate	63.28 ± 25.41	Higher than 81 mm	14 (30%)	0.320
CD14, µg/mL	5.13 ± 2.10	Less than 3.5 µg/mL	9 (20%)	0.030
IL-10, pg/mL	17.98 ± 14.44	Less than 11.1 pg/mL	17 (37%)	0.700
IL-6, pg/mL	2.82 ± 6.18	Equal or higher than 1.3 pg/mL	18 (39%)	0.600
IL-1β, 1 pg/mL	1.32 ± 0.92	Less than 1.0 pg/mL	22 (48%)	0.850
TNF-α, pg/mL	11.47 ± 4.33	Less than 6.0 pg/mL	3 (7%)	0.180
TLR4, pg/mL	632.85 ± 442.02	Less than 451 pg/mL	19 (41%)	0.440
LBP, pg/mL	39.94 ± 17.17	Equal or higher than 41 pg/mL	18 (39%)	0.620

* p = 0.04 if two outgroup samples are removed.




Fig. 1 – The taxonomic profiles of urine, gut and blood samples obtained from patients on peritoneal dialysis: (A) phylum and (B) family levels.

Comparison of OTUs

In this study *Gardnerella* OTUs were exclusively found in urogenital samples (in 20 out of 46 samples). *Dermabacter* and *Atopobium* OTUs were rarely observed in gut and blood samples

(in 1 and 2 samples, respectively), but more frequently found in urine (6 samples were positive for *Dermabacter* and 13 samples for *Atopobium*). There were other taxonomic groups only found in urogenital samples (see [supplementary Table S1](#)). When urine OTUs were compared with OTUs in gut and blood




Fig. 2 – Principal coordinate analysis of urinary, fecal and blood samples collected from patients on peritoneal dialysis. Distinct microbiomes are observed.

samples, some similarities were also observed. There were three OTUs (identified as *Pseudomonas* and *Stenotrophomonas*) common for all patients included in this study, and two OTUs (identified as *Pelomonas* and *Escherichia-Shigella*) presented in more than 90% of the patients. Interestingly, there were some OTUs found in multiple samples from a single patient (e.g. urine and blood). A set of 54 OTUs were common to multiple samples from a single patient, being 39 of these OTUs (72%) found in urogenital and fecal samples. Only 9 OTUs (17%) were simultaneously observed in urogenital and blood

samples (17%), and 6 OTUs (11%) were observed in fecal and blood samples. Similarities were also high when the analysis was extended to OTUs present in more than one patient, suggesting a high interplay between taxa in urogenital and gut microbiomes.

Association between taxonomic groups and demographic and clinical factors

Demographic and clinical variables of CKD-PD patients were studied to find correlations with the urogenital microbiome (Table 2), being the largest significance found for gender ($p=0.001$), particularly of *Lactobacillus* linked to females and other families, such as *Staphylococcus* and *Anaerococcus*, to males (Fig. 4). Fig. 4 shows the taxonomic groups significantly affected by the separation of urogenital samples in two groups according to different clinical variables. Patients with more than $3.5 \mu\text{g/mL}$ soluble CD14 levels showed increased levels of *Lactobacillus*, *Dermabacter*, and *Gardnerella* in urine microbiome ($p=0.03$) when compared with patients with equal or lower levels of sCD14 (Fig. 4). Lower relative abundance of *Atopobium*, *Dermabacter*, and *Gardnerella* were found in diabetic CKD-PD patients ($p=0.055$; $p=0.04$ by removing two outgroup samples as shown in supplementary Fig. S1). Residual diuresis lower than or equal to $1500 \text{ mL}/24 \text{ h}$, proteinuria, and C_{creat} lower than $50 \text{ L}/\text{week}$ were also associated to differences in the PD urobiome, while longer periods on PD (>5 years) and albumin did not significantly affect the urobiome (Table 2); multiple taxa were associated to these microbiome differences (Fig. 4 and supplementary Fig. S1). Curiously, patients with residual diuresis lower than or equal to $1500 \text{ mL}/24 \text{ h}$ also showed a lower Shannon diversity (median value of 1.66) than patients with normal values (median value of 2.41).

History of peritonitis was also associated with differences in the urogenital microbiome, being *Gardnerella*, *Staphylococcus*,




Fig. 3 – Sample subtypes observed among the urobiome of patients on peritoneal dialysis. Each subtype is dominated by a specific taxonomic group (genus), namely *Lactobacillus*, *Staphylococcus*, *Streptococcus*, *Gardnerella*, *Prevotella*, *Escherichia-Shigella*, or other subtypes (no specific genus dominates this subset of samples).




Fig. 4 – Post hoc analyses describing prevalence differences of multiple taxonomic groups (and *p* values associated to each taxa) considering the clinical and demographic factors associated to urobiome; all the remaining taxa not displayed in the figures are similar in both groups of patients – the figure displays only the differences. Gender, sCD14, residual diuresis, history of peritonitis, proteinuria and creatinine clearance were significantly associated to urobiome profiles ($p < 0.05$; see Table 2 with values for the analysis of similarities (ANOSIM) and confirmed by permutational multivariate analysis of variance (PERMANOVA). Post hoc analyses were done in STAMP 2.1.3.

and *Corynebacterium* decreased in such patients (Fig. 4). Previous peritonitis was reported in 11 patients, being caused by *Staphylococcus epidermidis* ($n = 2$), *Streptococcus salivarius* ($n = 2$), *Rhizobium radiobacter*, *Klebsiella oxytoca*, *Streptococcus mitis*, *Pantoea* spp., *Serratia marcescens*, while no agents were identified in 4 cases. Also, there were 4 cases of reported urinary infections (occurring more than three months before samples collection) among these patients, being caused by *E. coli* ($n = 2$), *Streptococcus haemolyticus* ($n = 1$) and one agent was unidentified. Neither the history of peritonitis, nor previous urinary infection was associated to particular subtypes described above and in Fig. 3.

In our work, we also measured markers of intestinal translocation (endotoxins, LPS-binding protein, TLR4, and sCD14), inflammatory parameters (C-reactive protein, ferritin, sedimentation velocity, IL-1 β , IL-6, TNF- α , and the anti-inflammatory IL-10), and other routine laboratory parameters (such as urea, proteinuria, albumin, hemoglobin, cholesterol and its different fractions, triglycerides, calcium, parathormone, BNP), but no statistically significant differences were found (Table 2). No difference was observed on the urogenital microbiome of patients depending on their PD modality (automated or manual).

Discussion

Urobiome relevance in CKD-PD and other CKD patients

The existence of an urobiome has been recognized since 2010³⁷ and multiple studies have described its diversity and complexity.^{16,17,28,30,38} The urinary microbiome has not been previously described in CKD-PD patients; these patients preserve residual renal function. In the present study, the urogenital microbiome of CKD-PD patients showed a lower biodiversity (Shannon index) compared to gut and blood microbiomes, as described for other non-PD-CKD patients.²⁵ The gut and blood microbiome profiles were recently published for CKD-PD patients.⁷ We found that the urogenital microbiome of our patients was distinct from the gut and blood microbiome and presented some exclusive taxa such as *Gardnerella*.

In our population, the urobiome was dominated by Bacilota, Actinomycetota and Pseudomonadota, specifically by the families Streptococcaceae, Enterobacteriaceae, Lactobacillaceae, and Bifidobacteriaceae, as previously described for CKD patients stages 3–5 that were not on dialysis.³⁰ The urine

subtypes described in this set of samples agreed with the previously described subtypes,^{30,39} being dominated by the genera *Lactobacillus*, *Staphylococcus*, *Streptococcus*, *Gardnerella*, *Prevotella*, and *Escherichia-Shigella*, suggesting that such subtypes may be transversal to distinct groups of CKD patients³⁰ and may have a role in CKD pathophysiology. Interestingly, in the study of Kramer et al.³⁰ the urobiome diversity decreased as kidney function worsened and similar observation was seen in this study for CKD-PD patients with lower values of residual diuresis.

Demographic and clinical factors and urobiome

It has been recognized the impact of the urinary microbiome on recurrent urinary infections among women.⁴⁰ Patients with history of infections and antibiotic intake in the last three months were excluded, so no conclusions can be drawn about that in this study. Nevertheless, previous history of peritonitis was described as an important factor associated to changes in the urobiome in this study, being *Gardnerella*, *Staphylococcus*, and *Corynebacterium* decreased in these patients. It is possible that peritonitis promotes a microbial translocation to the bladder, and this may alter the patient urobiome persistently even after successful treatment. Catheter exit-site infections were not associated to urogenital microbiome differences in our PD patients.

Additionally, some clinical conditions, such as diabetes, dyslipidemia, older age, or gender,²⁸ have been associated with a decrease in the urogenital microbiome richness and other fluctuations in the urogenital microbiome. In line with previous reports, we found that gender and diabetes were associated to differences in CKD-PD urobiome, while age did not alter this microbiome. Regarding the gender, *Lactobacillus* was previously described in the urobiome of healthy and CKD women,³⁰ corroborating our findings. Moreover, we found *Staphylococcus* increased in the urobiome of CKD-PD men, also as previously described.³⁰

Residual diuresis, proteinuria, and creatinine clearance (C_{creat}) were associated to changes in the urobiome of our CKD-PD. We observed higher levels of *Corynebacterium* and *Staphylococcus* in patients with residual diuresis ≤ 1500 mL/24 h. The genera *Staphylococcus* and *Corynebacterium*, among others, have been shown to be increased in patients with urinary tract infection.⁴¹ Interestingly, we observed that urobiome diversity decreased with lower values of residual diuresis. Kramer et al.,³⁰ in a previous study in CKD patients not on dialysis, also showed that urobiome diversity decreased as kidney function worsened. The reduction in the residual diuresis is an indicator of loss of residual renal function and a risk factor for poor outcomes and prognosis in PD patients.⁴² So, the changes in the urobiome that accompany the loss of residual renal function in CKD-PD patients should be further explored. Some species of *Corynebacterium* have a potent ability to metabolize urea and some studies relate an increase of this bacterium to urinary calculi.^{26,43} We also observed that proteinuria and C_{creat} lower than 50 L/week were associated to different taxonomic groups in the CKD-PD urobiome. Still, such findings result from a low number of samples analyzed and should be further confirmed.

The levels of inflammatory parameters and intermediate size molecules clearance may be related to specific taxonomic groups frequently present in urine,^{23,40} but confirmatory studies supporting these associations are still lacking. Interestingly, in our study CKD-PD patients with higher sCD4 levels presented an increase in *Lactobacillus*, *Dermabacter*, and *Gardnerella*. CD14 is a human monocyte differentiation antigen that acts as a pattern recognition receptor by binding to pathogen-associated molecular patterns such as lipopolysaccharides (LPS), working as toll-like receptor (TLR) co-receptor for the detection of infections.⁴⁴ Particularly in CKD, higher levels of sCD14 have been associated to vascular calcification, cardiovascular disease and have been proposed as a predictor of all-cause mortality.^{7,45} sCD14 role in CKD-associated dysbiosis should be explored in future studies.

Origin of urogenital microorganisms

In this study, the depletion of OTUs of *Atopobium* or *Dermabacter*, and *Gardnerella* in our CKD-PD patients was significantly associated with history of diabetes, history of peritonitis, and lower levels of sCD14. *Gardnerella* has been identified in the urobiome of patients with history of high blood pressure²⁴ and has also been described in the vagina microbiome of healthy women and women with bacterial vaginosis.^{39,46} The increase of *Gardnerella* in the vagina and the urogenital microbiomes has been associated to disease. In our CKD-PD patients, the reduction of *Gardnerella* was associated to diabetes and history of peritonitis, but the specific role of this bacterium is still unclear in these patients. *Gardnerella* has been shown to be depleted in the urobiome of diabetic patients compared to healthy controls and was not found in a diabetes plus dyslipidemia cohort comparing with other cohorts (diabetes only, diabetes plus hypertension, and diabetes plus hypertension and dyslipidemia).⁴⁷

CKD-PD patients may present a different quantitative and qualitative microbial profile in gut, blood, and urine when compared to healthy individuals. Changes in the gut and blood microbiomes of CKD-PD patients have been previously reported.⁷ But there are no previous studies describing the urobiome of CKD-PD patients. In this study, we have described for the first time the urobiome of CKD-PD patients. Results showed shared OTUs between the gut, the blood, and the urine microbiomes. These similarities can be influenced by the uremic environment that promotes the disruption of intestinal tight junctions, and the translocation of gut taxonomic groups and toxins into the blood and other body fluids.¹⁵ Nonetheless, this is a unicentric, cross-sectional study. For this reason, future studies should explore unrecognized mobility pathways of the human microbiome through different body habitats, and its role in infections and systemic inflammation in CKD-PD patients.

Conclusion

CKD-PD patients presented a unique urogenital microbiome with lower biodiversity than gut and blood microbiomes. History of peritonitis and relevant clinical biomarkers of CKD were associated to variations in the urobiome. Depletion of

certain *Gardnerella*, *Staphylococcus*, *Corynebacterium*, *Lactobacillus*, or *Dermabacter* populations were observed in CKD-PD patients with history of diabetes, history of peritonitis and altered levels of sCD14. Further, multicentric studies will allow the better understanding of the mobility pathways of the human microbiome and the clarification of the impact of urobiome on CKD-PD patients outcomes, namely on the risk of peritonitis, loss of residual renal function, and recurrent urinary tract infections.

Ethical approval

The study was approved by the local Ethics Committee (approval reference 200/18) in accordance with the 1964 Helsinki declaration and its later amendments. All participants agreed to participate in the study after receiving detailed information on the study objectives and protocol, and the written informed consent was obtained from all patients.

Data availability

The data supporting reported results can be found at NCBI under BioProject: PRJNA819486.

Funding

R.A. was supported by Individual Call to Scientific Employment Stimulus – Second Edition (grant number CEECIND/01070/2018).

Competing interests

All authors declare no conflict of interest.

Appendix A. Supplementary data

Supplementary data associated with this article can be found, in the online version, at [doi:10.1016/j.nefro.2023.08.008](https://doi.org/10.1016/j.nefro.2023.08.008)

REFERENCES

1. System USRD: USRDS Annual Data Report: epidemiology of kidney disease in the United States. Bethesda: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2021.
2. Butt J, Adamson C, Docherty K, Vaduganathan M, Solomon S, Anand I, et al. Eligibility for pharmacological therapies in heart failure with reduced ejection fraction: implications of the new Chronic Kidney Disease Epidemiology Collaboration creatinine equation for estimating glomerular filtration rate. *Eur J Heart Fail.* 2022;24:861–6.
3. Daugirdas J, Blake P, Ing T. Handbook of dialysis. Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins; 2006.
4. Li P, Chow K, Cho Y, Fan S, Figueiredo A, Harris T, et al. ISPD peritonitis guideline recommendations: 2022 update on prevention and treatment. *Perit Dial Int.* 2022;42:110–53.
5. Simões-Silva L, Araujo R, Pestana M, Soares-Silva I, Sampaio-Maia B. The microbiome in chronic kidney disease patients undergoing hemodialysis and peritoneal dialysis. *Pharmacol Res.* 2018;130:143–51.
6. Lau W, Vaziri N. The leaky gut and altered microbiome in chronic kidney disease. *J Ren Nutr.* 2017;27:458–61.
7. Merino-Ribas A, Araujo R, Pereira L, Campos J, Barreiros L, Segundo M, et al. Vascular calcification and the gut and blood microbiome in chronic kidney disease patients on peritoneal dialysis: a pilot study. *Biomolecules.* 2022;12:867.
8. Crespo-Salgado J, Vehaskari V, Stewart T, Ferris M, Zhang Q, Wang G, et al. Intestinal microbiota in pediatric patients with end stage renal disease: a Midwest Pediatric Nephrology Consortium study. *Microbiome.* 2016;4:50.
9. Hu X, Ouyang S, Xie Y, Gong Z, Du J. Characterizing the gut microbiota in patients with chronic kidney disease. *Postgrad Med.* 2020;132:495–505.
10. Hu J, Zhong X, Liu Y, Yan J, Zhou D, Qin D, et al. Correlation between intestinal flora disruption and protein-energy wasting in patients with end-stage renal disease. *BMC Nephrol.* 2022;23:130.
11. Luo D, Zhao W, Lin Z, Wu J, Lin H, Li Y, et al. The effects of hemodialysis and peritoneal dialysis on the gut microbiota of end-stage renal disease patients, and the relationship between gut microbiota and patient prognoses. *Front Cell Infect Microbiol.* 2021;11:579386.
12. Zhou J, Yang C, Lei W, Yang Z, Chen J, Lin H, et al. Exploration of the correlation between intestinal flora and *Escherichia coli* peritoneal dialysis-related peritonitis. *BMC Nephrol.* 2022;23:76.
13. Simões-Silva L, Araujo R, Pestana M, Soares-Silva I, Sampaio-Maia B. Peritoneal microbiome in end-stage renal disease patients and the impact of peritoneal dialysis therapy. *Microorganisms.* 2020;8:173.
14. Shah NB, Allegretti AS, Nigwekar SU, Kalim S, Zhao S, Lelouvier B, et al. Blood microbiome profile in CKD: a pilot study. *Clin J Am Soc Nephrol.* 2019;14:692–701.
15. Morand A, Cornu F, Dufour J, Tsimaratos M, Lagier J, Raoult D. Human bacterial repertoire of the urinary tract: a potential paradigm shift. *J Clin Microbiol.* 2019;57:e00618–75.
16. Groah S, Pérez-Losada M, Caldovic L, Ljungberg I, Sprague B, Castro-Nallar E, et al. Redefining healthy urine: a cross-sectional exploratory metagenomic study of people with and without bladder dysfunction. *J Urol.* 2016;196:579–87.
17. Brubaker L, Gourdi J, Siddiqui N, Holland A, Halverson T, Limeria R, et al. Forming consensus to advance urobiome research. *mSystems.* 2021;6:e0137120.
18. Hrbacek J, Tlaskal V, Cermak P, Hanacek V, Zchoval R. Bladder microbiota are associated with clinical conditions that extend beyond the urinary tract. *Microorganisms.* 2022;10:874.
19. Karstens L, Asquith M, Davin S, Stauffer P, Fair D, Gregory W, et al. Does the urinary microbiome play a role in urgency urinary incontinence and its severity? *Front Cell Infect Microbiol.* 2016;6:78.
20. Wu J, Muthusamy A, Al-Ghalith G, Knights D, Guo B, Wu B, et al. Urinary microbiome associated with chronic allograft dysfunction in kidney transplant recipients. *Clin Transplant.* 2018;32:e13436.
21. Fok C, Gao X, Lin H, Thomas-White K, Mueller E, Wolfe A, et al. Urinary symptoms are associated with certain urinary microbes in urogynecologic surgical patients. *Int Urogynecol J.* 2018;29:1765–71.
22. Roth J, Cain M. Neuropathic bladder and augmentation cystoplasty. *Urol Clin North Am.* 2018;45:571–85.
23. Shoskes D, Altemus J, Polackwich A, Tucky B, Wang H, Eng C. The urinary microbiome differs significantly between patients with chronic prostatitis/chronic pelvic pain

- syndrome and controls as well as between patients with different clinical phenotypes. *Urology*. 2016;92:26–32.
24. Liu F, Zhang N, Jiang P, Zhai Q, Li C, Yu D, et al. Characteristics of the urinary microbiome in kidney stone patients with hypertension. *J Transl Med*. 2020;18:130.
 25. Xie J, Huang J, Huang X, Peng J, Yu Z, Yuan Y, et al. Profiling the urinary microbiome in men with calcium-based kidney stones. *BMC Microbiol*. 2020;20:41.
 26. Cappuccino L, Bottino P, Torricella A, Pontremoli R. Nephrolithiasis by *Corynebacterium urealyticum* infection: literature review and case report. *J Nephrol*. 2014;27:117–25.
 27. Bučević Popović V, Šitum M, Chow C, Chan L, Roje B, Terzić J. The urinary microbiome associated with bladder cancer. *Sci Rep*. 2018;8:12157.
 28. Jones-Freeman B, Chonwerawong M, Marcelino V, Deshpande A, Forster S, Starkey M. The microbiome and host mucosal interactions in urinary tract diseases. *Mucosal Immunol*. 2021;14:779–92.
 29. Thomas-White K, Forster S, Kumar N, Van Kuiken M, Putonti C, Stares M, et al. Culturing of female bladder bacteria reveals an interconnected urogenital microbiota. *Nat Commun*. 2018;9:1557.
 30. Kramer H, Kuffel G, Thomas-White K, Wolfe A, Vellanki K, Leehey D, et al. Diversity of the midstream urine microbiome in adults with chronic kidney disease. *Int Urol Nephrol*. 2018;50:1123–30.
 31. Rani A, Ranjan R, McGee H, Andropolis K, Panchal D, Hajjiri Z, et al. Urinary microbiome of kidney transplant patients reveals dysbiosis with potential for antibiotic resistance. *Transl Res*. 2017;181:59–70.
 32. McMullen A, Anderson N, Wallace M, Shupe A, Burnham C. When good bugs go bad: epidemiology and antimicrobial resistance profiles of *Corynebacterium striatum*, an emerging multidrug-resistant, opportunistic pathogen. *Antimicrob Agents Chemother*. 2017;61:e01111–7.
 33. Lluch J, Servant F, Paisse S, Valle C, Valiere S, Kuchly C, et al. The characterization of novel tissue microbiota using an optimized 16S metagenomic sequencing pipeline. *PLoS One*. 2015;10:e0142334.
 34. Escudie F, Auer L, Bernard M, Mariadassou M, Cauquil L, Vidal K, et al. FROGS: find, rapidly OTUs with galaxy solution. *Bioinformatics*. 2018;34:1287–94.
 35. Araujo R, Dunlap C, Barnett S, Franco C. Decoding wheat endosphere–rhizosphere microbiomes in *Rhizoctonia solani*-infested soils challenged by *Streptomyces* biocontrol agents. *Front Plant Sci*. 2019;10:1038.
 36. Parks D, Beiko R. Identifying biologically relevant differences between metagenomic communities. *Bioinformatics*. 2010;26:715–21.
 37. Nelson D, Van Der Pol B, Dong Q, Revanna K, Fan B, Easwaran S, et al. Characteristic male urine microbiomes associate with asymptomatic sexually transmitted infection. *PLoS One*. 2010;5:e14116.
 38. Burnham P, Dadhanian D, Heyang M, Chen F, Westblade LF, Suthanthiran M, et al. Urinary cell-free DNA is a versatile analyte for monitoring infections of the urinary tract. *Nat Commun*. 2018;9:2412.
 39. Price T, Hilt E, Thomas-White K, Mueller E, Wolfe A, Brubaker L. The urobiome of continent adult women: a cross-sectional study. *BJOG*. 2020;127:193–201.
 40. Burnett L, Hochstedler B, Weldon K, Wolfe A, Brubaker L. Recurrent urinary tract infection: association of clinical profiles with urobiome composition in women. *NeuroUrol Urodyn*. 2021;40:1479–89.
 41. Joyce C, Halverson T, Gonzalez C, Brubaker L, Wolfe A. The urobiomes of adult women with various lower urinary tract symptoms status differ: a re-analysis. *Front Cell Infect Microbiol*. 2022;12:860408.
 42. Brown E, Blake P, Boudville N, Davies S, de Arteaga J, Dong J, et al. International society for peritoneal dialysis practice recommendations: prescribing high-quality goal-directed peritoneal dialysis. *Perit Dial Int*. 2020;40:244–53.
 43. Hong S, Yang Y, Xu J, Xia Q, Wang S, Xun Y. The renal pelvis urobiome in the unilateral kidney stone patients revealed by 2bRAD-M. *J Transl Med*. 2022;20:431.
 44. Ciesielska A, Matyjek M, Kwiatkowska K. TLR4 and CD14 trafficking and its influence on LPS-induced pro-inflammatory signaling. *Cell Mol Life Sci*. 2021;78:1233–61.
 45. Poesen R, Ramezani A, Claes K, Augustijns P, Kuypers D, Barrows I, et al. Associations of soluble CD14 and endotoxin with mortality, cardiovascular disease, and progression of kidney disease among patients with CKD. *Clin J Am Soc Nephrol*. 2015;10:1525–33.
 46. Onderdonk A, Delaney M, Fichorova R. The human microbiome during bacterial vaginosis. *Clin Microbiol Rev*. 2016;29:223–38.
 47. Liu F, Ling Z, Xiao Y, Yang Q, Wang B, Zheng L, et al. Alterations of urinary microbiota in type 2 diabetes mellitus with hypertension and/or hyperlipidemia. *Front Physiol*. 2017;8:126.